RxDoctor Payments Data

Ara Sadaniantz

Cardiovascular Disease · Providence, RINPI 1992766679

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,268 of the $26,657 with a category attached, or 79.8%. 16 manufacturers reported payments, led by Amgen at 52.0% of the total. Reporting peaked in 2019 at $19,683 and has fallen 95.1% since, to $956 in 2021. Among cardiovascular disease clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,657in general payments, 2019–2025

Across 239 payments — averaging $111.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$14K
  • Johnson & Johnson$10K
  • E.r. Squibb & Sons, L.L.C.$622
  • Boehringer Ingelheim$558
  • Amarin Pharma, Inc.$435
  • Medtronic$246
  • plus $973 from 10 others

What the payments were for

  • Speaking & faculty fees$21,26880%
  • Travel & lodging$430%
  • Food & beverage$5,33320%
  • Education$120%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,657 in reported general payments places this provider in the 95th percentile of 86 cardiovascular disease providers in Rhode Island.

See all cardiovascular disease providers in Rhode Island

Other cardiovascular disease in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →